Safety and efficacy of fremanezumab in real clinical practice in patients with chronic migraine

Abstract

Objective: to evaluate the efficacy and safety of fremanezumab in patients with chronic migraine (CM) in real-life clinical practice.Material and methods. In a 12-week, open-label, prospective study, 27 patients (21 women and 6 men, mean age 41±10 years) with CM were administered with fremanezumab 225 mg subcutaneously monthly or 675 mg once (quarterly). We assessed changes in migraine attack intensity using a visual analogue scale (VAS), a reduction in the number of headache days per month by 50% or more, the impact of headache on daily activities (HIT-6 scale), adverse events (AEs) and tolerability of fremanezumab.Results. The number of migraine days per month decreased by 50% or more in 52%, 63% and 70% of patients at weeks 4, 8 and 12, respectively. In 26% of patients, the number of days with headaches was reduced by 75% or more by the end of the study. On average, the number of days with migraine decreased by 11.6 per month, with monthly injections – by 12.6 per month (p<0.01). In patients who had negative experience with treatment with two or more groups of preventive therapies, the number of days with migraine was reduced by an average of 10.6 per month (p<0.01). The pain intensity according to VAS decreased from 9 to 5.7 points (p<0.001), the HIT-6 index decreased from 66 to 55 points (p<0.001). AEs occurred in 26% of cases, were transient and did not lead to discontinuation of treatment.Conclusion. The efficacy and safety of the use of fremanezumab in CM in real-world clinical practice has been demonstrated.